Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
We are living through what might be the biggest shift in metabolic health history: the era of GLP-1s
9 A representative escalation path to 12 mg weekly: | Weeks | Weekly Dose | |---------|-------------| | 1 to 4 | 2 mg | | 5 to 8 | 4 mg | | 9 to 12 | 6 mg | | 13 to 16 | 8 mg | | 17 to 20 | 10 mg | | 21+ | 12 mg | Each step lasts four weeks rather than one, giving GI receptors and central satiety pathways substantially more time to adjust before the next increment
The dual GIP/GLP-1 mechanism is different and more potent
2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
US$ 29.58
US$ 25.98
US$ 28.23
US$ 20.26
US$ 22.74
US$ 25.55
US$ 25.34
US$ 22.02
